Apogee Therapeutics Inc.

1 month ago · benzinga.com

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

2 months ago · globenewswire.com

AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today reported second quarter 2026 financial results, recent corporate updates and pipeline progress. "The second quarter marked a transformational period for Apogee," said Michael Henderson, M.D.

2 months ago · defenseworld.net

Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $134.17, for a total value of $737,935.00. Following the transaction, the insider directly owned 168,498 shares of the company's stock, valued

2 months ago · businesswire.com

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apogee Therapeutics, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Apogee will receive $135.11 in cash for each share of Apogee that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.

2 months ago · zacks.com

Here is how Apogee Therapeutics Inc. (APGE) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

3 months ago · globenewswire.com

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.

3 months ago · prnewswire.com

NEW YORK, June 22, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Apogee Therapeutics, Inc. (NASDAQ: APGE ) related to its sale to AbbVie Inc. Under the terms of the proposed transaction, Apogee shareholders are expected to receive $135.11 per share in cash.

3 months ago · benzinga.com

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Monday.

3 months ago · benzinga.com

AbbVie Inc. (NYSE:ABBV) announced Monday that it has agreed to acquire Apogee Therapeutics (NASDAQ:APGE) in a cash deal valued at approximately $10.9 billion.

3 months ago · businesswire.com

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Apogee Therapeutics, Inc. (NASDAQ: APGE) to AbbVie for $135.11 per share in cash.Halper Sadeh encourages Apogee shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether Apogee and its board of directors violated the fede.